CSL appoints Deborah Waterhouse as CEO. CSL stock is valued at AUD 92.2 billion
Published on 10/21/2026 at 09:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLeadership transition and valuation
- Deborah Waterhouse will become CSL's CEO on February 1, 2027.
- Morgan Stanley lifted its target from AUD 182.00 to AUD 200.00 on October 20, 2026.
- CSL stock trades at EUR 121.55 at 9:29 a.m. CEST at Lang & Schwarz on October 21, 2026.
- CSL's annual general meeting is scheduled for October 27, 2026.
CSL (AU000000CSL8) stock was trading at EUR 121.55 at Lang & Schwarz on October 21, 2026, at 9:29 a.m. CEST. Reuters reported on October 21, 2026, that Deborah Waterhouse will become chief executive officer and managing director on February 1, 2027, with interim CEO Gordon Naylor remaining until the transition.
A new CEO for 2027
The appointment gives CSL a defined leadership timetable after a global search. Waterhouse currently leads ViiV Healthcare and has more than 25 years of experience in specialty pharmaceuticals, according to Motley Fool Australia on October 21, 2026.
What does the target change signal?
The broker view points to pipeline execution as the central valuation issue. Motley Fool Australia reported on October 20, 2026, that Morgan Stanley raised its CSL target from AUD 182.00 to AUD 200.00. The report linked the revision to CSL development agreements for VMX-C001 and lixudebart, including projected future revenue contributions.
Next date is October 27
CSL's next scheduled corporate date is its 2026 annual general meeting on October 27, 2026. The company lists Melbourne and online participation for the meeting on its CSL investor page.
Valuation meets succession
The leadership handover and the higher AUD 200.00 target put strategy and pipeline delivery alongside the immediate succession timetable. CSL stock was valued at AUD 92.2 billion in the Morgan Stanley discussion, while the euro quotation remained at EUR 121.55 at Lang & Schwarz during the October 21, 2026 session.
CSL stock was trading at EUR 121.55 at Lang & Schwarz on October 21, 2026 at 9:29 a.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of CSL stock.
CSL stock key data
- Company: CSL Limited
- ISIN: AU000000CSL8
- Ticker: CSL
- Primary exchange: ASX
- Price Lang & Schwarz (as of October 21, 2026, 9:29 a.m. CEST): EUR 121.55
- Market capitalization: AUD 92.2 billion (as of October 20, 2026)
- Sector / Industry: Health Care / Biotechnology
Market context: Market report S&P/ASX 200.
